Changeflow GovPing Pharma & Drug Safety Tricyclic KRAS Inhibitor Patent - Incyte Corpor...
Routine Notice Added Final

Tricyclic KRAS Inhibitor Patent - Incyte Corporation

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO granted Patent US12600717B2 to Incyte Corporation on April 14, 2026 for tricyclic compounds as inhibitors of KRAS activity. The patent contains 34 claims covering Formula I compounds useful in treating diseases associated with KRAS activity, including cancer. Filing date was July 13, 2022, under application number 17812310.

What changed

USPTO granted Incyte Corporation Patent US12600717B2 for tricyclic KRAS inhibitor compounds effective April 14, 2026. The patent contains 34 claims under CPC classification C07D 471/04 and covers Formula I compounds useful in treating KRAS-associated diseases including cancer. Inventors include Zhenwu Li, Zhiyong Yu, Jeremy Roach, and nine others. Filing date was July 13, 2022 under application 17812310.

Pharmaceutical companies developing KRAS-targeted cancer therapies should monitor this patent to assess potential freedom-to-operate considerations. The patent grants Incyte exclusive rights to these tricyclic compounds for the duration of the patent term.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Tricyclic compounds as inhibitors of KRAS

Grant US12600717B2 Kind: B2 Apr 14, 2026

Assignee

Incyte Corporation

Inventors

Zhenwu Li, Zhiyong Yu, Jeremy Roach, Gia Hoang, Bin Hu, Gencheng Li, Rory McAtee, Ken Mukai, Rocco Policarpo, Robert Susick, Xiaozhao Wang, Wenqing Yao

Abstract

Disclosed are compounds of Formula I (shown below), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

CPC Classifications

C07D 471/04

Filing Date

2022-07-13

Application No.

17812310

Claims

34

View original document →

Named provisions

Formula I compounds KRAS inhibition Cancer treatment

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600717B2

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Pharmaceutical compounds
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!